首頁 > 市場調查報告書 > 製藥

癌症生物製劑

市場調查報告書

商品編碼

1542427

全球癌症單株抗體市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

Global Cancer Monoclonal Antibodies Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 179 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球癌症單株抗體市場需求預計將從2023年的929.4億美元達到近4,354.3億美元的市場規模，2024-2032年研究期間的複合年成長率為18.72%。

癌症單株抗體 (mAb) 是實驗室生產的分子，經過改造可特異性結合癌細胞或參與癌症生長的蛋白質。這些抗體源自單一細胞克隆，針對癌細胞表面或內部存在的獨特抗原，為癌症治療提供精確的治療選擇。它們標記癌細胞以供免疫系統破壞、阻斷生長訊號或將細胞毒性劑直接遞送至腫瘤部位。單株抗體是癌症標靶治療不可或缺的一部分，可治療多種癌症，包括乳癌、淋巴瘤和白血病。它們的特異性和針對性方法有助於最大限度地減少對健康細胞的損害，使它們成為腫瘤學的關鍵進步。

市場動態

在全球癌症盛行率不斷上升的推動下，癌症單株抗體市場正在迅速擴大。與傳統治療相比，單株抗體提供的標靶治療由於其精確性和副作用減少而越來越受到青睞。這種精準醫療方法符合個人化醫療保健的成長趨勢，進一步推動市場成長。生物技術的進步和對癌症生物學了解的加深為開發創新單株抗體創造了新的機會。研究人員不斷發現新的標靶和途徑，創造出具有更高功效和安全性的下一代單株抗體。聯合療法的發展，即單株抗體與化療或免疫療法等其他治療方法一起使用，也擴大了它們的治療潛力和癌症單株抗體的市場範圍。

公共和私營部門對癌症研究和開發的投資不斷增加是推動癌症單株抗體市場的另一個關鍵因素。製藥公司正在積極尋求新的單株抗體和臨床試驗，產生穩定的潛在療法。此外，對早期癌症檢測和預防的日益重視預計將有助於更多地採用基於單株抗體的診斷方法。然而，高昂的開發和生產成本可能會阻礙市場成長。研究、開發和製造單株抗體所需的大量投資可能會限制可及性並影響整體市場擴張。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球癌症單株抗體市場的各個細分市場進行了包容性評估。癌症單株抗體產業的成長和趨勢為這項研究提供了整體方法。

市場區隔

癌症單株抗體市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按類型

人性化
人類
嵌合體
鼠類

按申請

血癌
乳癌
肺癌
黑色素瘤
大腸直腸癌
肝癌
其他

按最終用戶

醫院
研究所
其他

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲癌症單株抗體市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。癌症單株抗體市場的主要參與者包括羅氏有限公司、百時美施貴寶公司、默克公司、葛蘭素史克公司、強生公司、安進公司、諾華公司、阿斯特捷利康公司、禮來公司和公司，艾伯維。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：癌症單株抗體公司的競爭格局

癌症單株抗體市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

頂級公司市佔率分析
市場集中度
F. Hoffmann-La Roche Ltd.

公司概況
公司收入
產品
最新動態

Bristol Myers Squibb Co.

公司概況
公司收入
產品
最新動態

Merck & Co.

公司概況
公司收入
產品
最新動態

GlaxoSmithKline Plc

公司概況
公司收入
產品
最新動態

Johnson & Johnson

公司概況
公司收入
產品
最新動態

Amgen Inc.

公司概況
公司收入
產品
最新動態

Novartis AG

公司概況
公司收入
產品
最新動態

AstraZeneca Plc

公司概況
公司收入
產品
最新動態

Eli Lilly And Company

公司概況
公司收入
產品
最新動態

AbbVie

公司概況
公司收入
產品
最新動態

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR11216177

The global demand for Cancer Monoclonal Antibodies Market is presumed to reach the market size of nearly USD 435.43 Billion by 2032 from USD 92.94 Billion in 2023 with a CAGR of 18.72% under the study period 2024-2032.

Cancer monoclonal antibodies (mAbs) are laboratory-produced molecules engineered to bind specifically to cancer cells or proteins involved in cancer growth. Derived from a single clone of cells, these antibodies target unique antigens present on or within cancer cells, offering precise therapeutic options for cancer treatment. They mark cancer cells for destruction by the immune system, block growth signals, or deliver cytotoxic agents directly to the tumor site. Monoclonal antibodies are integral to targeted cancer therapies, addressing various cancers, including breast, lymphoma, and leukemia. Their specificity and targeted approach help minimize damage to healthy cells, making them a pivotal advancement in oncology.

MARKET DYNAMICS

The cancer monoclonal antibodies market is expanding rapidly, fueled by the propelling prevalence of cancer worldwide. Monoclonal antibodies offer targeted therapy that is increasingly preferred due to its precision and reduced side effects compared to traditional treatments. This precision medicine approach aligns with the growing trend towards personalized healthcare, further boosting market growth. Advancements in biotechnology and an improved understanding of cancer biology are creating new opportunities for developing innovative monoclonal antibodies. Researchers continuously discover novel targets and pathways, creating next-generation mAbs with enhanced efficacy and safety profiles. The development of combination therapies, where monoclonal antibodies are used alongside other treatments such as chemotherapy or immunotherapy, also expands their therapeutic potential and cancer monoclonal antibodies market reach.

The increasing investment in cancer research and development by the public and private sectors is another key factor driving the cancer monoclonal antibodies market. Pharmaceutical companies are actively pursuing new mAbs and clinical trials, leading to a steady pipeline of potential therapies. Additionally, the growing emphasis on early cancer detection and prevention is expected to contribute to the increased adoption of monoclonal antibody-based diagnostics. However, high development and production costs may hinder market growth. The substantial investment required to research, develop, and manufacture monoclonal antibodies can limit accessibility and affect overall market expansion.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Cancer Monoclonal Antibodies. The growth and trends of Cancer Monoclonal Antibodies industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Cancer Monoclonal Antibodies market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Humanized
Human
Chimeric
Murine

By Application

Blood Cancer
Breast Cancer
Lung Cancer
Melanoma
Colorectal Cancer
Liver Cancer
Others

By End-user

Hospitals
Research Institutes
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Cancer Monoclonal Antibodies market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Cancer Monoclonal Antibodies market include F. Hoffmann-La Roche Ltd., Bristol Myers Squibb Co., Merck & Co., GlaxoSmithKline Plc, Johnson & Johnson, Amgen Inc., Novartis AG, AstraZeneca Plc, Eli Lilly And Company, AbbVie. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. CANCER MONOCLONAL ANTIBODIES - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By End-user
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS BY TYPE

5.1. Overview By Type
5.2. Historical and Forecast Data Analysis By Type
5.3. Humanized Historic and Forecast Sales By Regions
5.4. Human Historic and Forecast Sales By Regions
5.5. Chimeric Historic and Forecast Sales By Regions
5.6. Murine Historic and Forecast Sales By Regions

6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS BY APPLICATION

6.1. Overview By Application
6.2. Historical and Forecast Data Analysis By Application
6.3. Blood Cancer Historic and Forecast Sales By Regions
6.4. Breast Cancer Historic and Forecast Sales By Regions
6.5. Lung Cancer Historic and Forecast Sales By Regions
6.6. Melanoma Historic and Forecast Sales By Regions
6.7. Colorectal Cancer Historic and Forecast Sales By Regions
6.8. Liver Cancer Historic and Forecast Sales By Regions
6.9. Others Historic and Forecast Sales By Regions

7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS BY END-USER

7.1. Overview By End-user
7.2. Historical and Forecast Data Analysis By End-user
7.3. Hospitals Historic and Forecast Sales By Regions
7.4. Research Institutes Historic and Forecast Sales By Regions
7.5. Others Historic and Forecast Sales By Regions

8. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE CANCER MONOCLONAL ANTIBODIES COMPANIES

9.1. Cancer Monoclonal Antibodies Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF CANCER MONOCLONAL ANTIBODIES INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. F. Hoffmann-La Roche Ltd.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Bristol Myers Squibb Co.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Merck & Co.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. GlaxoSmithKline Plc
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Johnson & Johnson
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Amgen Inc.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Novartis AG
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. AstraZeneca Plc
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Eli Lilly And Company
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. AbbVie
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments